
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization ...
Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong …